<DOC>
	<DOCNO>NCT02253888</DOCNO>
	<brief_summary>The objective trial establish bioequivalence Tipranavir ( TPV ) 250 mg self emulsify drug delivery system ( SEDDS ) capsule store controlled temperature 30°C control relative humidity ( RH ) 70 % comparison TPV 250 mg SEDDS capsule store control refrigerated condition 2°C 8°C</brief_summary>
	<brief_title>Bioequivalence Study Tipranavir Stored Controlled Temperature Compared With Tipranavir Stored Controlled Refrigerated Conditions , Orally Co-administered With Ritonavir Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<criteria>1 . Healthy male females complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG clinical laboratory test : No finding abnormal clinical relevance No evidence clinically relevant concomitant disease Acceptable laboratory value indicate adequate baseline organ function time screen . Laboratory value consider acceptable severity less equal Grade 1 , accord AIDS Clinical Trials Group ( ACTG ) Division Acquired Immunodeficiency Syndrome ( National Institute Allergy Infectious Diseases / National Institutes Health ) ( DAIDS ) Grading Scale within normal reference range laboratory parameter define DAIDS . Participation subject abnormal laboratory value great Grade 1 ( e.g. , Creatine phosphokinase ( CPK ) , amylase , triglyceride ) subject approval Boehringer Ingelheim Pharmaceuticals , Inc. ( BIPI ) clinical monitor 2 . Age ≥18 ≤60 year 3 . Body mass index ( BMI ) ≥18.5 ≤35.0 kg/m2 4 . Signed date write informed consent admission study , accordance Good Clinical Practice ( GCP ) local legislation concern volunteer capable understand give informed consent 5 . Willingness subject abstain ingest follow food substance begin 2 week administration study medication end study : grapefruit grapefruit juice , red wine , Seville oranges , St. John 's Wort Milk Thistle 6 . Willingness subject abstain use alcohol within 72 hour administration study medication end study 7 . Willingness subject abstain follow substance within 72 hour administration study medication : garlic supplement methylxanthine contain food drink ( include coffee , tea , cola , energy drink , chocolate , etc . ) 1 . Chronic gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 2 . Surgery gastrointestinal tract ( except appendectomy ) 3 . Diseases central nervous system ( epilepsy , cerebral cramp ) psychiatric disorder neurological disorder 4 . History relevant orthostatic hypotension , faint spell blackouts 5 . Chronic relevant acute infection 6 . History allergy hypersensitivity ( include drug allergy ) deem relevant trial , judge investigator 7 . Intake drug long halflife ( &gt; 24 hour ) within 1 month less 10 halflives drug administration study drug trial 8 . Use drug might reasonably influence result trial ( base knowledge time protocol 's preparation ) within 10 day administration study drug trial 9 . Participation another trial investigational drug within 30 day administration study drug trial . 10 . Smoker ( 10 cigarette per day , 3 cigar per day 3 pipe per day ) 11 . Inability refrain smoke 24 hour receive study medication trial day pharmacokinetic ( PK ) data collect 12 . High level alcohol use ( 60 gram per day ) 13 . Illicit drug use ( i.e. , positive urine test illicit prescription nonprescription drug drug abuse ) 14 . Veins unsuited i.v . puncture either arm ( e.g. , vein difficult locate , access puncture vein tendency rupture puncture ) 15 . Blood donation ( 100 mL within 4 week administration study medication trial ) 16 . History bleed disorder acute blood coagulation defect 17 . Hypersensitivity RTV related antiretroviral drug 18 . Extreme physical activity ( within 1 week administration study medication trial ) 19 . Any laboratory value outside reference range &gt; DAIDS Grade 1 clinical relevance 20 . Heart rate screen &gt; 90 bpm &lt; 45 bpm 21 . Seated systolic blood pressure either &lt; 95 mm Hg &gt; 160 mm Hg 22 . Any screen ECG value outside reference range clinical relevance 23 . Inability adhere dietary regimen study centre 24 . For female subject : Pregnancy plan become pregnant within 60 day study completion Positive pregnancy test Nonuse barrier method contraception least 3 month participation study Not willing unable use reliable method barrier contraception ( diaphragm spermicidal cream/jelly condoms spermicidal foam ) , 2 month completion/termination trial Chronic use oral contraception hormone replacement contain ethinyl estradiol Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>